SavedAdd your journal

Journals / Journal of the Turkish-German Gynecological Association / 2007 / Cilt: 8 - Sayı: 4

Üreme çağındaki polikistik over sendromlu hastalarda metabolik sendrom sıklığı ve farklı metabolik sendrom tanı ölçütlerinin karşılaştırılması

The frequency of metabolic syndrome in women with polycystic ovaries at reproductive age and comparison of different diagnostic criteria formetabolic syndrome

TeomanT KILIÇ
Harika BODUR
Eray ÇALIŞKAN
Şahin ZETEROĞLU
Pages
402–407
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As the most important approach for treatment and management of MetS against future cardiovascular events is the preventive strategy, categorizing more women with MetS according to the most discriminative criteria can also be a useful method for identifying the individuals under greater risk to prevent the developmental effects of MetS in patients with PCOS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the frequency of the metabolic syndrome (MetS) by using different criteria in women with polycystic ovary syndrome (PCOS).
📊
Key Findings & Data:Materials and Methods: The study group consisted of 182 patients diagnosed with PCOS according to the Rotterdam criteria and 182 age matched controls.
💡
Conclusion & Impact:As the most important approach for treatment and management of MetS against future cardiovascular events is the preventive strategy, categorizing more women with MetS according to the most discriminative criteria can also be a useful method for identifying the individuals under greater risk to prevent the developmental effects of MetS in patients with PCOS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the frequency of the metabolic syndrome (MetS) by using different criteria in women with polycystic ovary syndrome (PCOS). Materials and Methods: The study group consisted of 182 patients diagnosed with PCOS according to the Rotterdam criteria and 182 age matched controls. MetS frequency was separately investigated in the two groups according to the National Cholesterol Education Program Expert Panel (NCEP), World Health Organization (WHO), American Heart Association/National Heart Lung Blood Institute (AHA/NCLBI), International Diabetes Federation (IDF) and the Rotterdam MetS criteria. Results: Except for the AHA/NCLBI criterion, all criteria showed significantly higher MetS prevalence in patients with PCOS as compared to the control group. This difference was more prominent especially at younger age. The highest frequency of MetS (26%) was observed according to the International Diabetes Federation (IDF) definition. The lower cutoff values of waist circumference and fasting glucose level in the IDF criteria has made it the most discriminative MetS definition for identifying risky individuals for MetS in patients with PCOS. Discussion: Development of MetS may begin at younger ages in PCOS patients by using IDF, NCEP and Rotterdam criteria. As the most important approach for treatment and management of MetS against future cardiovascular events is the preventive strategy, categorizing more women with MetS according to the most discriminative criteria can also be a useful method for identifying the individuals under greater risk to prevent the developmental effects of MetS in patients with PCOS.

Özet

Amaç: Farklı tanı ölçütleri kullanarak polikistik over sendromlu (PKOS) hastalarda metabolik sendrom sıklığını (MetS) araştırmak.Materyal ve Metot: Rotterdam ölçütlerine göre PKOS tanısı konulmuş 182 kadın çalışma grubunu oluştururken, yaşa göre eşleştirilmiş 182 kadın da kontrol grubunu oluşturdu. Her iki grupta da MetS sıklığı Ulusal Kolesterol Eğitim programı (NCEP: National Cholesterol Education Program Expert Panel), Dünya Sağlık Örgütü (WHO: World Health Organization), Amerikan Kalp Derneği/Ulusal Kalp Akciğer Kan Enstitüsü (AHA/NCLBI: American Heart Association/National Heart Lung Blood Institute), Uluslararası Diyabet Federasyonu (IDF: International Diabetes Federation) ve Rotterdam MetS kriterleri kullanılarak araştırıldı. Sonuçlar: PKOS grubunda AHA/NCLBI dışındaki diğer tüm ölçütlerle MetS tanısı konulmuş hasta sıklığı kontrol grubundan fazlaydı. Bu fark, özellikle daha genç yaşlarda daha belirgindi. En yüksek MetS sıklığı tanısı %26 ile IDF ölçütlerine göre konuldu. Bel çevresi ve açlık kan glukozunda kullanılan düşük kesme değerleri IDF ölçütlerini MetS tanısında en ayırt edici ölçütler yapmaktadır. Bu ölçütler PKOS hastalarında riskli kadınların ayırt edilmesinde ve MetS’e bağlı ileride oluşacak etkilerin önlenmesinde kullanılabilir. Tartışma: IDF, NCEP ve Rotterdam ölçütleri göstermektedir ki, PKOS’lu kadınlarda MetS oluşumu daha genç yaşlarda başlayabilir. MetS’in gelecekteki kardiyovasküler etkilerinin tedavisi ve yönetimindeki en önemli strateji önleme olduğu için en ayırt edici ölçütler kullanılarak daha fazla kadını MetS olarak tanımlamak riskli kadınların MetS’in gelecekteki etkilerinden korunmalarını sağlayabilir.

🔖

Cite This Article

KILIÇ, T., BODUR, H., ÇALIŞKAN, E., ZETEROĞLU, Ş. (2022). Üreme çağındaki polikistik over sendromlu hastalarda metabolik sendrom sıklığı ve farklı metabolik sendrom tanı ölçütlerinin karşılaştırılması. Journal of the Turkish-German Gynecological Association, Cilt: 8 - Sayı: 4, 402–407. https://ajindex.com/articles/567970

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III): Final Report. Bethesda, MD. National Heart, Lung and Blood Institute; 2002
  2. Report of a WHO consultation. In: Alwan A, King H, eds. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: Word Health Organization, Department of Noncommunicable Disease Surveillance; 1999:1-59
  3. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005; 112:2735-52
  4. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome; a new worldwide definition. Lancet 2005;366:1059-62
  5. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002;105:2696-8
  6. McGill HC Jr, McMahan CA, Herderick EE et al. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002;105:2712-8
  7. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25
  8. Wild RA. Long-term health consequences of PCOS. Hum Reprod Update 2002;8:231-41
  9. Legro RS. Polycystic ovary syndrome and cardiovascular disease: A premature association? Endocrine Rev 2003;24:302-12
  10. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84(1):165-9
  11. Glueck CJ, Papanna R, Wang P et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovary syndrome. Metabolism 2003;52(7):908-15
  12. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-35
  13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAM